Local Phase 4 Pan-European SMART Study: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Local Phase 4 Pan-European SMART Study (NCT00463866), a randomized phase 4 study. The primary outcome is Number of Severe Asthma Exacerbations Per Participant..

2. Clinical Question

The main question is about the frequency of severe exacerbations during the stated treatment period, rather than a comparison of time until the first event alone. The primary outcome description refers to time to first severe exacerbation translated to a mean number of severe exacerbations per participant. That wording makes the event-count summary the main quantity to interpret, while leaving the precise operational analysis details unclear.

The registry’s primary comparison is between two SMART maintenance-dose regimens. It therefore addresses the relative results for those two regimens in the population enrolled, not whether either regimen is better than no treatment or another type of asthma care. The record does not report enough detail about eligibility, baseline characteristics, or treatment delivery to define more narrowly which adults with asthma the results represent.

3. Trial Design

This was a Phase 4, randomized, parallel-group study with no masking reported. The registry identifies AstraZeneca as the sponsor and lists the study as completed. The study start is recorded as 2007-03. Its brief summary describes a 6 month treatment period for adult patients with asthma.

The intervention is listed as the drug budesonide/formoterol, with the study summary referring to Symbicort Maintenance And Reliever Therapy. The two arm labels are “Symbicort® SMART®) 1*2” and “Symbicort® SMART®) 2*2.” The registry describes these as different maintenance doses, but the meaning of the notation in the labels is not reported in the registry record. The comparison is between these active regimens.

The posted primary outcome is the number of severe asthma exacerbations per participant over 6 months. The record defines a severe exacerbation as deterioration in asthma requiring oral or systemic glucocorticosteroids for at least 3 days, and/or hospitalisation or an emergency-room visit with oral or systemic glucocorticosteroid treatment. The secondary outcomes cover the fraction of participants with a severe exacerbation, exacerbations leading to hospitalisation or emergency-room treatment, steroid-treatment days during severe exacerbations, as-needed medication use, asthma control, steroid dose, and cost.

The registry records enrollment as 8424. The primary arm summaries list 4008 participants for the 1*2 regimen and 4045 for the 2*2 regimen. The registry record does not report the trial’s original sample-size justification, allocation concealment details, treatment adherence, participant flow, analysis populations, or a detailed statistical analysis plan. It also does not report whether interim analyses were planned or conducted. Those omissions mean that the posted design description can establish the broad randomized, parallel, open-label structure, but not all details needed to reconstruct how the trial was run or analyzed.

The registry lists nine outcome measures, including the primary outcome, and eight secondary outcome titles. It does not list registered outcome analyses. The posted outcome summaries and recalculated comparisons therefore should be distinguished from a complete record of the trial’s prespecified analysis methods.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Severe Asthma Exacerbations Per Participant., measured over 6 months.

The primary endpoint is the mean number of severe asthma exacerbations per participant during 6 months. It focuses on serious worsening of asthma that meets the registry’s stated treatment or care-use definition: oral or systemic glucocorticosteroids for at least 3 days, and/or a hospitalisation or emergency-room visit with oral or systemic glucocorticosteroid treatment.

An event-count measure is useful because exacerbations can recur. A mean count per participant describes the average event burden over the treatment period, rather than only whether a participant experienced any event. The registry reports this outcome as severe exacerbations per participant and gives the full range in each arm. The summary does not provide a standard deviation for this endpoint.

The outcome description also says “time to first severe asthma exacerbation,” translated to a mean number of exacerbations per participant. These are distinct ways of framing an outcome: time to first event concerns how long it takes for an initial event, while a mean count can reflect repeated events. The record does not explain the translation or provide the detailed endpoint calculation method. For interpretation, the posted arm values and the rate-ratio comparison relate to the reported event count per participant, and should not be treated as a detailed time-to-event analysis.

Because the endpoint counts events within a defined treatment period, its interpretation depends on the event definition and the period of observation. It does not by itself describe asthma control between exacerbations, duration of each event, or outcomes beyond the stated 6 months. The secondary outcomes address some related aspects, but do not change what the primary endpoint measures.

7. Results Posted in the Registry

• Symbicort® SMART®) 2*2: 0.08 versus 0.10 (Severe exacerbations per participant) on control; rate ratio 0.82 (95% CI 0.67–1.02, approximate, Poisson model); p ≈ 0.070.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Fraction of Participants With Severe Asthma Exacerbation

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Symbicort® SMART®) 2*2: mean 0.08 versus 0.10 on control; difference -0.02 (95% CI -0.03 to -0.00), standardized effect d = -0.05; z-test p = 0.041.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Symbicort® SMART®) 2*2 than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Total Number of Severe Asthma Exacerbations That Led to Hospitalisation and/or Emergency Room Treatment.

• Endpoint type: Event rate: events per unit of follow-up, compared as a rate ratio.
• Test: Poisson rate ratio, based on the estimated number of events and follow-up time.
• Result:
  • Symbicort® SMART®) 2*2: 0.01 versus 0.01 (Number of events per participant) on control; rate ratio 0.76 (95% CI 0.41–1.39, approximate, Poisson model); p ≈ 0.372.
• Interpretation:
  • The 95% confidence interval includes no difference (a ratio of 1), so these data do not show a statistically significant difference between Symbicort® SMART®) 2*2 and the control. The interval gives the range of effects that remain compatible with the data.

Total Number of Days Per Participant With Oral/Systemic Glucocorticosteroids During Severe Asthma Exacerbation

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Symbicort® SMART®) 2*2: mean 9.10 versus 9.60 on control; difference -0.50 (95% CI -0.80 to -0.20), standardized effect d = -0.07; z-test p = 0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Symbicort® SMART®) 2*2 than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The secondary outcomes extend the primary question to whether participants experienced any severe exacerbation, whether exacerbations involved hospitalisation or emergency-room treatment, and how much time was spent receiving oral or systemic glucocorticosteroids during severe exacerbations. Other listed outcomes concern as-needed medication, asthma control, steroid dose, and cost. These outcomes provide a broader picture of the questions registered for the study, but they are not substitutes for the primary count outcome.

For the secondary outcomes with detailed numerical results, the direction of the posted comparisons is broadly consistent with the primary numerical pattern: the 2*2 arm has lower summaries for the reported event and steroid-day measures. This directional consistency can be informative, but the measures have different scales and definitions. It does not establish that all aspects of asthma control moved together, nor does it convert the separate estimates into one overall treatment effect.

The secondary estimates should carry less weight than the primary comparison for several reasons. They are unadjusted, the registry does not report a strategy for controlling multiplicity, and it does not identify which secondary analyses were prespecified as confirmatory. Examining multiple outcomes creates more opportunities for an apparently strong result to arise by chance. A secondary p-value therefore needs to be read in the context of the complete set of outcomes and an analysis plan, neither of which is fully documented in the registry record.

The registry names eight secondary outcomes, while the detailed numerical summaries reported in the results data cover three. The other listed topics indicate the scope of planned assessment, but their numerical findings cannot be evaluated from the posted summaries. No conclusion about those unreported numerical comparisons should be inferred from the available secondary results.

Taken together, the secondary outcomes can help describe whether the primary numerical direction is accompanied by related patterns. They do not resolve the primary interval’s uncertainty, establish a clinically important difference, or provide independent confirmation without a documented multiplicity and analysis strategy. Their proper role is supportive and exploratory in the context of this registry record.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Fraction of Participants With Severe Asthma Exacerbation
• Total Number of Severe Asthma Exacerbations That Led to Hospitalisation and/or Emergency Room Treatment.
• Total Number of Days Per Participant With Oral/Systemic Glucocorticosteroids During Severe Asthma Exacerbation
• Mean Daily Number of Inhalations of As-needed Medication.
• Percent of Participants With a Well Controlled Asthma Week.
• Mean Overall Asthma Control Questionnaire (ACQ) Score
• The Mean Total Daily Dose of Steroids From Symbicort.
• Mean Cost Per Participant Per Country

9. Statistical Interpretation

10. Statistical Methods Explained

The registry presents arm-level means and a rate-ratio comparison for the primary count outcome. The comparison and the other displayed inferential comparisons are unadjusted recalculations from the posted summary statistics. The registry does not list outcome analyses, so these recalculations should not be confused with a fully documented trial analysis plan or with a confirmed description of the sponsor’s original inferential model.

What does a rate ratio express?

A rate ratio compares event rates between two groups. A value of 1 corresponds to equal rates; a value below 1 indicates a lower estimated rate in the arm in the numerator, and a value above 1 indicates a higher estimated rate. For the primary comparison, the estimated rate ratio is below 1, with the 2*2 arm compared with the 1*2 arm. The ratio expresses a relative contrast; it does not give the absolute number of events prevented or establish clinical importance.

The arm-level primary means, 0.097 and 0.08 severe exacerbations per participant, provide the corresponding descriptive scale. The result is an event rate per participant over the recorded treatment period, not a proportion of participants with at least one event. A participant can contribute more than one event to a count outcome, whereas a fraction-with-event outcome records whether an event occurred. Those measures answer related but different questions.

Why use a count model?

Count outcomes are often analyzed using models that relate event counts to exposure time. A Poisson model is one common approach, and the posted primary recalculation is identified as Poisson. In general, the basic Poisson model assumes that the variability of counts follows a particular relationship with their mean. If actual event counts are more variable than that assumption allows, over-dispersion can make standard errors too small and intervals too narrow. If counts are less variable, the model may also fit poorly. These are general statistical considerations; the registry record does not report a diagnostic assessment of dispersion or whether an alternative count model was considered in the trial’s own analysis.

The primary outcome summary gives a full range but no standard deviation. A range identifies only the smallest and largest observed values. It cannot show the frequency of zero-event observations, the concentration of repeated events among some participants, or the shape of the overall distribution. The absence of that distributional detail limits independent assessment of how well a particular count model fits.

What does the unadjusted p-value tell the reader?

The primary p-value is 0.07 and is explicitly unadjusted. In general, a p-value measures how unusual data at least as incompatible with a specified null model would be if that null model were true, under the assumptions of the analysis. It is not the probability that the null hypothesis is true, nor does it measure the size or clinical importance of a difference. The registry does not report whether this p-value is the result of the trial’s prespecified analysis or identify a prespecified decision threshold for the primary comparison.

Randomization supports a comparison between assigned groups, but it does not by itself document how the analysis handled missing measurements, non-adherence, protocol deviations, or repeated events. The record does not report those details. The calculation should therefore be interpreted as a summary-based, unadjusted comparison rather than as a complete reconstruction of the trial’s analysis.

How should the secondary comparisons be understood?

The secondary results use different summaries, including a fraction of participants with an event, an event rate for hospitalisation or emergency-room treatment, and a mean for steroid-treatment days. A mean difference is a difference on the outcome’s original scale; a rate ratio is a relative comparison of event rates. These estimates cannot be compared as though they were the same measure. Their confidence intervals and unadjusted p-values describe uncertainty for their respective outcomes, not a single combined effect.

The reported secondary p-values are unadjusted. When researchers examine multiple outcomes, the chance of at least one apparently unusual result can increase if no adjustment or other multiplicity strategy is used. The registry record does not report a multiplicity plan. That makes the secondary findings useful for describing patterns, but less conclusive than a single prespecified primary comparison. The reported analyses field is empty, and the record does not document which secondary comparisons, if any, were confirmatory.

Confidence intervals are another part of the inferential summary. In general, a confidence interval reflects the precision of an estimate under the assumptions of the method. A narrow interval indicates greater precision than a wide interval, but neither width nor a p-value resolves whether an effect matters clinically. For the primary rate ratio, the interval includes 1, so the data do not rule out equal rates at the confidence level represented by that interval.

Any method description beyond the posted unadjusted summary-based recalculations remains uncertain. The registry record does not report the original analysis plan, model diagnostics, adjustment variables, or a detailed explanation of how the primary outcome’s time-to-first wording relates to its mean event-count summary. These omissions prevent a reader from verifying the trial’s original analytical choices from the registry record alone.

11. Confidence Intervals and Precision

The primary rate-ratio confidence interval crosses 1, the null value for a ratio. This means the interval includes equal rates as well as values on either side. The point estimate lies below 1, but its direction alone does not establish that the underlying rates differ. The unadjusted p-value of 0.07 is consistent with uncertainty about the direction and size of the primary contrast under the stated calculation.

A confidence interval is generally a range of estimates compatible with the data and the method’s assumptions. It is not a statement that there is a particular probability that the true effect lies within the observed interval. Its interpretation depends on the statistical model and the quality of the underlying data. The registry does not report model diagnostics or enough detail to assess all those assumptions for the trial’s own analysis.

The secondary outcome for the fraction of participants with a severe exacerbation reports 95% confidence intervals for each arm and a comparison interval that does not include zero. The secondary steroid-days comparison also has an interval that excludes zero. Those features describe the summary-based comparisons; the secondary p-values are unadjusted, and multiple outcomes were listed. They should not be read as a multiplicity-adjusted confirmation of the primary result.

Precision differs across outcomes and depends on the measure and its variability. The primary outcome reports a full range rather than a standard deviation, and the registry does not show individual participant data. Consequently, the posted summaries do not reveal the distribution of event counts or how much a small number of participants with repeated events may influence the mean. The interval around the primary rate ratio is more informative about uncertainty in the comparison than the arm ranges, but it remains conditional on the recalculation’s assumptions.

Statistical precision is also distinct from clinical importance. The registry record does not specify what difference in exacerbation rates would be meaningful to participants or clinicians. The confidence interval can describe statistical uncertainty, but it cannot supply that missing clinical threshold.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size figures are planning illustrations based on the observed effect, not a report of the trial’s original design calculation. For the displayed planning scenarios, the figures are participants per arm, not total events. The planning assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The effect to detect is the stated fraction of the observed effect. The general note says that time-to-event tables give total event counts using the Schoenfeld approach; the other planning figures are participants per arm.

The 80% power column describes the planned number of participants per arm under which a study would have an 80% chance of detecting the specified effect, if that effect and the planning assumptions were correct. The 90% column applies the same idea at a higher probability of detecting that effect. These are design probabilities for hypothetical future studies, not probabilities that the posted result is true.

The rows use different fractions of the observed effect. Planning for a smaller effect requires more participants, because a smaller signal is harder to distinguish from random variation. The curve expresses the same general relationship between the assumed effect and the planning requirement; its values depend on the stated assumptions. The original trial’s sample-size justification and design assumptions are not reported in the registry record. These illustrations are not observed power.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, λ₀ and λ₁ are event rates per patient-year, and T is follow-up per participant in years. This assumes Poisson counts and equal follow-up.

Worked calculation for this trial

1. Control rate λ₀ = 0.0970; treatment rate λ₁ = 0.0800 events per patient-year; follow-up T = 0.50 years.
2. n = (1.96 + 0.842)² × (1/0.0970 + 1/0.0800) / (0.50 × [ln(0.825)]²) = 9,644.0, rounded up to 9,644 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
lambda0 <- 0.097                      # control rate, events per patient-year
lambda1 <- 0.08                      # treatment rate
tt      <- 0.5                       # follow-up per participant, years
n_per_arm <- function(power, frac = 1) {
  l1 <- lambda0 * (lambda1 / lambda0)^frac   # smaller effect = fraction of the observed log rate ratio
  ceiling(round((z_a + qnorm(power))^2 * (1 / lambda0 + 1 / l1) / (tt * log(l1 / lambda0)^2), 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Simulation 1: Poisson counts. Simulation 2: over-dispersed counts (variance = 1.5 x mean), analysed with the matching variance.
set.seed(463866)
n    <- n_per_arm(0.80)
reps <- 20000
m0 <- lambda0 * n * tt; m1 <- lambda1 * n * tt
x0 <- rpois(reps, m0); x1 <- rpois(reps, m1)
z  <- log(x1 / x0) / sqrt(1 / x0 + 1 / x1)
cat(sprintf("Simulated power, Poisson counts, n = %s per arm: %.3f\n", format(n, big.mark = ","), mean(abs(z) > z_a, na.rm = TRUE)))
phi <- 1.5
y0 <- rnbinom(reps, mu = m0, size = m0 / (phi - 1)); y1 <- rnbinom(reps, mu = m1, size = m1 / (phi - 1))
z2 <- log(y1 / y0) / sqrt(phi * (1 / y0 + 1 / y1))
cat(sprintf("Simulated power, over-dispersed counts (phi = 1.5), same n: %.3f\n", mean(abs(z2) > z_a, na.rm = TRUE)))

Output from running the code

100% of observed effect: n per arm = 9,644 (80% power), 12,911 (90% power)
 75% of observed effect: n per arm = 16,703 (80% power), 22,361 (90% power)
 50% of observed effect: n per arm = 36,635 (80% power), 49,043 (90% power)
Simulated power, Poisson counts, n = 9,644 per arm: 0.806
Simulated power, over-dispersed counts (phi = 1.5), same n: 0.623

The first simulation draws Poisson counts and should land close to the target power. The second allows extra variability (variance 1.5 times the mean, a purely illustrative value), which lowers the power at the same sample size, so rate trials usually need more participants than the Poisson formula suggests.

14. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary outcome and eight secondary outcome titles, but it does not report a multiplicity strategy. Multiplicity matters when several outcomes or comparisons are examined: without adjustment or a clearly defined hierarchy, the chance of at least one nominally unusual result can rise. The secondary comparisons are explicitly unadjusted, so their p-values should not be treated as if they control the overall error rate across all outcomes.

The registry record does not report whether the primary outcome was tested under a prespecified analysis plan, whether secondary outcomes were confirmatory or exploratory, or whether any hierarchy governed interpretation. It lists no outcome analyses. The posted summaries therefore do not establish which comparisons were planned as the main inferential tests before the data were examined.

Missing-data handling is not reported in the registry record. The record does not say how missing outcome measurements were treated, whether participants with incomplete follow-up were included in each analysis, or whether sensitivity analyses assessed the effect of missingness. This is important because the posted group counts do not by themselves show the number of participants contributing usable data to every outcome or the reasons for any differences.

Analysis populations are also not reported in the registry record. It is therefore not possible to determine from the registry whether the outcome summaries were based on all randomized participants, participants who received treatment, participants who completed follow-up, or another defined population. The record does not report how protocol deviations, treatment discontinuation, or adherence were handled.

The original sample-size justification, analysis model details, adjustment variables, and interim-analysis plans are not reported in the registry record. Those details should not be inferred from the planning illustrations or the unadjusted recalculations. The absence of this information does not prove that the trial lacked such procedures; it means that they cannot be assessed from the registry record.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 1% reporting threshold.

Most frequent serious adverse event terms

Serious events with the highest arm-level rate: asthma (0.3%), cholelithiasis (0.1%), breast cancer (0.1%), pneumonia (0.1%), osteoarthritis (0.1%).

The registry reports serious adverse events for each arm, with 4008 participants at risk and 77 affected in the 1*2 arm, and 4045 at risk and 88 affected in the 2*2 arm. These are arm-level serious-adverse-event counts. They are not, by themselves, evidence that the events were caused by the intervention, and the registry summary does not provide a causal assessment for each event.

The listed serious-event terms include Asthma at 0.3%; Cholelithiasis, Breast Cancer, Pneumonia, and Osteoarthritis at 0.1% each; and Atrial Fibrillation at 0.0%. The record does not provide enough detail in these summaries to interpret those listed terms as a comparative risk analysis between arms. The percentages should be read as posted, not as a substitute for full event narratives or an adjusted comparison.

The other adverse-event field is recorded as 0 for each arm. Death counts are not reported in the registry record. The posted safety figures do not describe event timing, severity beyond the serious classification, relatedness, or the complete participant-level safety experience. They should be read as registry summaries rather than as a comprehensive safety assessment.

16. What the Result Does, and Does Not, Mean

The results describe a randomized comparison of two active Symbicort SMART maintenance-dose regimens in adults with asthma over 6 months. The primary posted means are 0.097 severe exacerbations per participant in the 1*2 arm and 0.08 in the 2*2 arm. The unadjusted rate-ratio estimate is below 1, but its confidence interval includes 1 and the unadjusted p-value is 0.07. The numerical direction and the uncertainty need to be considered together.

These data do not establish that one regimen is clinically superior. The registry record does not define a clinically meaningful difference, and the primary interval does not rule out equal rates. Nor does the comparison establish that either regimen is effective relative to placebo or another form of asthma treatment, because the comparator was another active SMART regimen.

The study’s stated period is 6 months. The results therefore do not establish what would happen over a longer period, in a different population, or under different treatment conditions. The record describes adult patients with asthma but does not report detailed eligibility criteria or baseline characteristics in the summary. Generalization beyond the enrolled population is consequently uncertain.

The primary outcome focuses on severe exacerbations as defined by the registry. It does not fully describe everyday symptoms, asthma control between events, quality of life, adherence, or other outcomes. Some related measures appear among the secondary outcomes, but the secondary comparisons are unadjusted and are not a replacement for evidence on the primary endpoint.

The registry’s open-label design means masking was not reported. The record does not explain how this design may have affected treatment behavior, event reporting, or decisions related to care. It also does not report missing-data procedures, analysis populations, or detailed model checks. Those limits prevent a complete assessment of possible bias and analytical robustness from the registry record alone.

The findings are best understood as an uncertain estimate of the relative event-rate contrast between the two recorded regimens in this trial. They do not provide medical advice, prove an absence of difference, or establish effects beyond the particular outcome definitions, comparison, and follow-up period recorded.

17. Why This Trial Matters Statistically

This trial is statistically instructive because its primary outcome is an event count rather than a simple continuous measurement or a binary indicator. Counting severe exacerbations can retain information about recurrence: participants may contribute no events or multiple events. That makes the distinction between a mean event rate and the fraction of participants with any event important. The registry includes both kinds of summaries, which address related but different questions.

The comparison also illustrates why a point estimate should not be interpreted in isolation. The primary estimate is numerically below the ratio value corresponding to equal rates, yet the confidence interval crosses that null value and the unadjusted p-value is 0.07. A directional estimate is not the same as a precise or conclusive finding. Reading the interval alongside the estimate makes the uncertainty more visible.

Count data can pose modeling challenges when event frequencies vary substantially among participants. A Poisson approach is one common framework, but it relies on assumptions about the relationship between the mean and variability. The registry provides arm summaries and ranges, not the participant-level distribution or a model-diagnostics report. This makes the endpoint a useful example of why the choice and checking of a count model matter, while also limiting what can be concluded about the original analysis.

The record further illustrates the distinction between registered outcomes and registered analyses. It names a primary endpoint and multiple secondary outcomes but lists no outcome analyses. The unadjusted comparisons can describe the posted summaries, but they do not reveal the prespecified model, analysis population, missing-data plan, or multiplicity strategy. Statistical interpretation depends not only on the numbers but also on these design and analysis details.

Finally, the planning illustrations show how assumptions about the effect to detect shape sample-size requirements. They are design scenarios based on the observed effect, not a measure of the evidence generated by the completed trial. Keeping planning calculations separate from observed results is essential to avoid treating a hypothetical future design as proof of the current study’s power or conclusions.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
• Rate comparisons use a Poisson approximation unless the sponsor posted confidence limits; real event counts are often over-dispersed.

The registry record leaves important details unavailable for interpreting this particular comparison. It does not report specific eligibility criteria, baseline asthma severity, or other baseline characteristics in the study summary. Without these details, readers cannot assess how closely the enrolled participants represent a particular clinical population or whether the arms had notable baseline differences.

The study was open-label, and the record does not describe procedures for outcome ascertainment or whether event classification was independently reviewed. Since severe exacerbations include treatment and health-care-use criteria, the absence of detail about assessment procedures limits evaluation of how consistently events were identified. This does not show that ascertainment was biased; it means the registry record does not allow that possibility to be assessed.

The primary outcome description combines “time to first” language with a mean number of events per participant. The record does not explain how these concepts were operationalized together. The posted rate comparison and arm means support interpretation as a count or rate summary, but do not supply the detailed analytical definition needed to reconstruct the endpoint calculation.

The primary range does not describe the distribution of counts, and no standard deviation is reported for that outcome. The registry does not provide participant-level data, model diagnostics, or enough information to assess over-dispersion. The displayed Poisson recalculation is therefore a summary-based analysis whose assumptions cannot be fully checked from the record.

Finally, the registry does not report missing-data handling, analysis populations, adherence, treatment discontinuation, the original sample-size rationale, or a multiplicity plan. These gaps are particularly relevant when interpreting unadjusted secondary results and assessing whether the posted summaries reflect all randomized participants. These are limitations of what the registry record documents; they do not establish that the trial team did not address the issues in other trial materials.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: Local Phase 4 Pan-European SMART Study — NCT00463866.
• Registry record last updated 2010-03-22; status last verified 2010-03.
• Results first posted 2010-03-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

The registry record describes a completed Phase 4 randomized, parallel, open-label study of two budesonide/formoterol Symbicort SMART maintenance-dose regimens in adults with asthma. The stated treatment period was 6 months, and enrollment was 8424.

The primary outcome was the mean number of severe asthma exacerbations per participant. The posted means were 0.097 in the 1*2 arm and 0.08 in the 2*2 arm. The unadjusted rate-ratio comparison was below 1, with a confidence interval that includes 1 and an unadjusted p-value of 0.07. These results describe a numerical contrast with uncertainty, rather than establishing a definitive difference.

The registry lists eight secondary outcome titles and reports numerical summaries for three in the posted results data. Secondary comparisons are unadjusted. The record does not list outcome analyses or report the original analysis plan, multiplicity strategy, missing-data methods, analysis populations, or original sample-size justification. The planning illustrations are based on the observed effect and stated assumptions, not the trial’s original design calculation.

Serious adverse events were reported in both arms; deaths are not reported in the registry record. Overall interpretation is limited to the recorded comparison, definitions, and 6-month period.